Efficiency VELs can cut Research and Development time by up to 75% because millions of mutations are identified and embedded into the vaccine for future immunology. Years of development reacting to the ever evolving mutations are eliminated through our platform's implementation. Cost Savings Because of the greatly reduced time for Research and Development, the resulting cost savings is enormous. The average vaccine costs approximately $2 Billion to bring to market. VELs will reduce the cost by as much as $1.5 Billion, increasing revenue and competitive advantages. Agnostic Platform Whether the vaccine producer uses mRNA, viral vector, synthetic peptide, or any other delivery platform, VELs will integrate seamlessly to combat present and future strains of that virus or cancer. Unique Platform There is no other immunological tool like VEL. Toxicity VELs have very low toxicity. There are no side effects reported from the use of VELs. Cross-disease efficacy No other biotechnology has created a solution for both infectious diseases and cancer. This is an historic development in the field of medicine.